24 results match your criteria suvr maximum

  • Page 1 of 1

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Alzheimers Res Ther 2021 04 17;13(1):80. Epub 2021 Apr 17.

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.

Background: Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia.

Methods: BAN2401-G000-201 aimed to establish the effective dose 90% (ED90), defined as the simplest dose that achieves ≥90% of the maximum treatment effect. Read More

View Article and Full-Text PDF

In vivo detection of beta-amyloid at the nasal cavity and other skull-base sites: a retrospective evaluation of ADNI1/GO.

Ann Nucl Med 2021 Jun 12;35(6):728-734. Epub 2021 Apr 12.

Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada.

Introduction: Amyloid beta (Aβ) is partially cleared from the CSF via skull base perivascular and perineural lymphatic pathways, particularly at the nasal cavity. In vivo differences in Aβ level at the nasal cavity between patients with Alzheimer's disease (AD), subjects with mild cognitive impairment (MCI) and cognitively normal (CN) individuals have not been previously assessed.

Methods: This is a retrospective evaluation of subject level data from the ADNI-1/GO database. Read More

View Article and Full-Text PDF

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images.

Eur J Nucl Med Mol Imaging 2021 Jul 12;48(7):2183-2199. Epub 2021 Apr 12.

Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Background: [F]flutemetamol PET scanning provides information on brain amyloid load and has been approved for routine clinical use based upon visual interpretation as either negative (equating to none or sparse amyloid plaques) or amyloid positive (equating to moderate or frequent plaques). Quantitation is however fundamental to the practice of nuclear medicine and hence can be used to supplement amyloid reading methodology especially in unclear cases.

Methods: A total of 2770 [F]flutemetamol images were collected from 3 clinical studies and 6 research cohorts with available visual reading of [F]flutemetamol and quantitative analysis of images. Read More

View Article and Full-Text PDF

Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program.

J Prev Alzheimers Dis 2021 ;8(2):218-223

Claire Roberts, Eisai Ltd., Hatfield, UK, Email: Phone: +44 8456 761 590.

Background/objectives: Elenbecestat, an oral BACE-1 inhibitor that has been shown to reduce Aβ levels in cerebrospinal fluid, was investigated in two global phase 3 studies in early AD. Here we report on differences observed in characteristics of APOE ε4 and amyloid positive subjects in the large screening cohort.

Design: Screening was performed in 5 sequential tiers over a maximum of 80 days, as part of placebo controlled, double blind phase 3 studies. Read More

View Article and Full-Text PDF

F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Magnetic Resonance for Diagnosing Adult-Onset Still's Disease.

Front Med (Lausanne) 2020 22;7:544412. Epub 2020 Oct 22.

Rheumatology Unit, Department of Medicine, Padova University Hospital, Padova, Italy.

The objective of the study was to assess the advantages of F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography with magnetic resonance (PET/CT-MR) in diagnosing and monitoring patients with adult-onset Still's disease (AOSD). Participants in this retrospective case-control study underwent whole-body F-FDG-PET/CT-MR imaging. All PET scans were qualitatively and semiquantitatively analyzed using standardized uptake values (SUVs) normalized to liver uptake, i. Read More

View Article and Full-Text PDF
October 2020

Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation.

Ann Nucl Med 2020 Sep 13;34(9):629-635. Epub 2020 Jun 13.

Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Objective: Visual evaluation is the standard for amyloid positron emission tomography (PET) examination, though the result depends upon the physician's subjective review of the images. Therefore, it is expected that objective quantitative evaluation is useful for image interpretation. In this study, we examined the usefulness of the quantitative evaluation of amyloid PET using a PET-only quantification method in comparison with visual evaluation. Read More

View Article and Full-Text PDF
September 2020

Customized FreeSurfer-based brain atlas for diffeomorphic anatomical registration through exponentiated lie algebra tool.

Ann Nucl Med 2020 Apr 22;34(4):280-288. Epub 2020 Feb 22.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 20 Eonjuro 63-gil, Gangnam-gu, Seoul, Republic of Korea.

Objective: Digital brain template and atlas designed for a specific group provide advantages for the analysis and interpretation of neuroimaging data, but require a significant workload for development. We developed a simple method to create customized brain atlas for diffeomorphic anatomical registration through exponentiated lie algebra (DARTEL) tool using FreeSurfer-generated volume-of-interest (FSVOI) images and validated.

Methods: F-florbetaben positron emission tomography (PET) and magnetic resonance (MR) imaging data were obtained from 248 participants of Alzheimer's disease spectrum (from cognitively normal to Alzheimer's disease dementia). Read More

View Article and Full-Text PDF

Temporal and anatomical distribution of F-flutemetamol uptake in canine brain using positron emission tomography.

BMC Vet Res 2020 Jan 17;16(1):17. Epub 2020 Jan 17.

Veterinary Teaching Hospital, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, 28644, South Korea.

Background: Positron emission tomography (PET) is increasingly being used as an imaging modality for clinical and research applications in veterinary medicine. Amyloid PET has become a useful tool for diagnosing Alzheimer's disease (AD) in humans, by accurately identifying amyloid-beta (Aβ) plaques. Cognitive dysfunction syndrome in dogs shows cognitive and pathophysiologic characteristics similar to AD. Read More

View Article and Full-Text PDF
January 2020

Diagnostic Efficacy of F-FDG PET/MRI in Peripheral Nerve Injury Models.

Neurochem Res 2019 Sep 3;44(9):2092-2102. Epub 2019 Aug 3.

Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

The aim of this study was to evaluate the diagnostic efficacy of F-FDG PET/MRI in two different peripheral neuropathic pain models using the injured rat sciatic nerves. Twelve rats, with operation on left sciatic nerves, were evenly divided into three groups: sham surgery (control group), crushing injury and chronic constriction injury (CCI) (experimental groups). The nerve damage was assessed at 3 weeks postoperatively using following methods: paw withdrawal threshold values (RevWT), maximum standardized uptake values on PET/MRI images (SUVR), and counting the number of myelinated axons in proximal and distal sites of nerve injury (MAxR). Read More

View Article and Full-Text PDF
September 2019

Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging.

Radiol Phys Technol 2018 Dec 16;11(4):451-459. Epub 2018 Oct 16.

Division of Radiation Informatics for Medical Imaging, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Japan.

With the increasing incidence of dementia worldwide, the frequent use of amyloid and tau positron emission tomography imaging requires low-dose protocols for the differential diagnoses of various neurodegenerative diseases and the monitoring of disease progression. In this study, we investigated the feasibility to reduce the PET dose without a significant loss of quantitative accuracy in 3D dynamic row action maximum likelihood algorithm-reconstructed PET images using [C]PIB and [F]THK5351. Eighteen cognitively normal young controls, cognitively normal elderly controls, and patients with probable Alzheimer's disease (n = 6 each), were included. Read More

View Article and Full-Text PDF
December 2018

Clinical value of delayed 18F-FDG PET/CT for predicting nipple-areolar complex involvement in breast cancer: A comparison with clinical symptoms and breast MRI.

PLoS One 2018 12;13(9):e0203649. Epub 2018 Sep 12.

Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, South Korea.

Objective: We aimed to evaluate the predictive value of delayed 18F-FDG PET/CT for identifying malignancies involved in the nipple-areolar complex (NAC) in comparison with clinical symptoms and breast MRI.

Methods: We enrolled 90 patients who underwent preoperative delayed 18F-FDG PET/CT and MRI between October 2015 and May 2017. We calculated the NAC-Standardized uptake value ratio (SUVR) using the following formula: maximum SUV (SUVmax) of the NAC in the malignant breast /SUVmax of the NAC in the contralateral normal breast on early (NAC-SUVRearly) and delayed (NAC-SUVRdelay) phase images. Read More

View Article and Full-Text PDF
February 2019

Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study.

Front Oncol 2018 22;8:18. Epub 2018 Feb 22.

Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

Introduction: This pilot study aimed at exploring the utility of the proliferation tracer F-18 fluorothymidine (FLT) and positron-emission tomography (PET)/magnetic resonance imaging (MRI) (FLT-PET/MRI) for early treatment monitoring in patients with melanoma brain metastasis (MBM) who undergo targeted therapy or immunotherapy.

Material And Methods: Patients with newly diagnosed MBM underwent baseline and follow-up FLT-PET/MRI scans at 3-4 weeks of targeted therapy or immunotherapy. Up to six measurable brain lesions ≥1. Read More

View Article and Full-Text PDF
February 2018

Positron emission tomography-guided magnetic resonance spectroscopy in Alzheimer disease.

Ann Neurol 2018 04 10;83(4):771-778. Epub 2018 Apr 10.

Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.

Objective: To determine whether the level of metabolites in magnetic resonance spectroscopy (MRS) is a representative marker of underlying pathological changes identified in positron emission tomographic (PET) images in Alzheimer disease (AD).

Methods: We performed PET-guided MRS in cases of probable AD, mild cognitive impairment (MCI), and healthy controls (HC). All participants were imaged by C-Pittsburgh compound B ( C-PiB) and F-fluorodeoxyglucose ( F-FDG) PET followed by 3T MRS. Read More

View Article and Full-Text PDF

Validation of Noninvasive Tracer Kinetic Analysis of F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

J Nucl Med 2018 07 24;59(7):1104-1110. Epub 2017 Nov 24.

Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and.

Accurate amyloid PET quantification is necessary for monitoring amyloid-β accumulation and response to therapy. Currently, most of the studies are analyzed using the static SUV ratio (SUVR) approach because of its simplicity. However, this approach may be influenced by changes in cerebral blood flow (CBF) or radiotracer clearance. Read More

View Article and Full-Text PDF

FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment.

Radiology 2017 05 19;283(2):508-514. Epub 2016 Oct 19.

From the Department of Radiology (C.L.S., L.F., P.K.R.), Department of Neurology, Neuro-Oncology Center (D.S.), and Department of Public Health Sciences (J.T.P.), University of Virginia, 1215 Lee St, Charlottesville, VA 22908.

Purpose To determine the correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in patients with glioblastoma and suspected progression at posttherapy magnetic resonance (MR) imaging. Materials and Methods The authors retrospectively examined the relationship between metabolic activity at FDG PET in the residual lesion identified at brain MR imaging and survival time in 56 patients with glioblastoma who were treated with postoperative concurrent radiation and temozolomide therapy and who underwent FDG PET/computed tomography because of radiologic deterioration at follow-up MR imaging between 2006 and 2015. A normalized metric of metabolic activity in the residual lesion (standardized uptake value ratio [SUV]) was calculated as the maximum standardized uptake value (SUV) in the tumor relative to that in healthy white matter. Read More

View Article and Full-Text PDF

Evaluation of MLACF based calculated attenuation brain PET imaging for FDG patient studies.

Phys Med Biol 2017 04 6;62(7):2542-2558. Epub 2017 Feb 6.

Research and clinical collaborations, Siemens Molecular Imaging, Knoxville, TN, United States of America.

Calculating attenuation correction for brain PET imaging rather than using CT presents opportunities for low radiation dose applications such as pediatric imaging and serial scans to monitor disease progression. Our goal is to evaluate the iterative time-of-flight based maximum-likelihood activity and attenuation correction factors estimation (MLACF) method for clinical FDG brain PET imaging. FDG PET/CT brain studies were performed in 57 patients using the Biograph mCT (Siemens) four-ring scanner. Read More

View Article and Full-Text PDF

Motion correction in simultaneous PET/MR brain imaging using sparsely sampled MR navigators: a clinically feasible tool.

EJNMMI Phys 2015 Dec 16;2(1):14. Epub 2015 Jul 16.

3982 Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.

Background: We present a study performing motion correction (MC) of PET using MR navigators sampled between other protocolled MR sequences during simultaneous PET/MR brain scanning with the purpose of evaluating its clinical feasibility and the potential improvement of image quality.

Findings: Twenty-nine human subjects had a 30-min [(11)C]-PiB PET scan with simultaneous MR including 3D navigators sampled at six time points, which were used to correct the PET image for rigid head motion. Five subjects with motion greater than 4 mm were reconstructed into six frames (one for each navigator) which were averaged to one image after MC. Read More

View Article and Full-Text PDF
December 2015

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.

Neuroimage Clin 2015 27;7:105-13. Epub 2014 Nov 27.

Queensland Brain Institute, Clem Jones Centre for Ageing Dementia Research, The University of Queensland, Brisbane, Qld 4072, Australia.

The brains of patients suffering from Alzheimer's disease (AD) have three classical pathological hallmarks: amyloid-beta (Aβ) plaques, tau tangles, and neurodegeneration, including that of cholinergic neurons of the basal forebrain. However the relationship between Aβ burden and basal forebrain degeneration has not been extensively studied. To investigate this association, basal forebrain volumes were determined from magnetic resonance images of controls, subjects with amnestic mild cognitive impairment (aMCI) and AD patients enrolled in the longitudinal Alzheimer's Disease Neuroimaging Initiative (ADNI) and Australian Imaging, Biomarkers and Lifestyle (AIBL) studies. Read More

View Article and Full-Text PDF
September 2015

Radiobiological Modeling Based on F-Fluorodeoxyglucose Positron Emission Tomography Data for Esophageal Cancer.

J Nucl Med Radiat Ther 2014 ;5

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, 21201, USA.

Background: We investigated the relationship of standardized uptake values (SUVs) to radiobiological parameters, such a 25 s tumor control probability (TCP), to allow for quantitative prediction of tumor response based on SUVs from F fluorodeoxyglucose (F-FDG) positron emission tomography (PET) before and after treatment for esophageal cancer.

Methods: We analyzed data from 20 esophageal cancer patients treated with chemoradiotherapy (CRT) followed by surgery. Tumor pathologic response to CRT was assessed in surgical specimens. Read More

View Article and Full-Text PDF
January 2014

Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.

Neuroimage 2014 Jan 20;84:843-53. Epub 2013 Sep 20.

Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany.

We previously investigated the progression of β-amyloid deposition in brain of mice over-expressing amyloid-precursor protein (APP-Swe), a model of Alzheimer's disease (AD), in a longitudinal PET study with the novel β-amyloid tracer [(18)F]-florbetaben. There were certain discrepancies between PET and autoradiographic findings, which seemed to arise from partial volume effects (PVE). Since this phenomenon can lead to bias, most especially in the quantitation of brain microPET studies of mice, we aimed in the present study to investigate the magnitude of PVE on [(18)F]-florbetaben quantitation in murine brain, and to establish and validate a useful correction method (PVEC). Read More

View Article and Full-Text PDF
January 2014

Brain β-amyloid load approaches a plateau.

Neurology 2013 Mar 27;80(10):890-6. Epub 2013 Feb 27.

From the Departments of Radiology, Mayo Clinic, Rochester, MN, USA.

Objective: To model the temporal trajectory of β-amyloid accumulation using serial amyloid PET imaging.

Methods: Participants, aged 70-92 years, were enrolled in either the Mayo Clinic Study of Aging (n = 246) or the Mayo Alzheimer's Disease Research Center (n = 14). All underwent 2 or more serial amyloid PET examinations. Read More

View Article and Full-Text PDF

Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC?

AJNR Am J Neuroradiol 2013 Apr 18;34(4):758-64. Epub 2012 Oct 18.

Centre for Clinical Research, Discipline of Medical Imaging, University of Queensland, St Lucia, Brisbane, Australia.

Background And Purpose: There is significant interest in whether diffusion-weighted MR imaging indices, such as the minimum apparent diffusion coefficient, may be useful clinically for preoperative tumor grading and treatment planning. To help establish the pathologic correlate of minimum ADC, we undertook a study investigating the relationship between minimum ADC and maximum FDOPA PET uptake in patients with newly diagnosed glioblastoma multiforme.

Materials And Methods: MR imaging and FDOPA PET data were acquired preoperatively from 15 patients who were subsequently diagnosed with high-grade brain tumor (WHO grade III or IV) by histopathologic analysis. Read More

View Article and Full-Text PDF

The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.

Hematol Oncol 2011 Jun 15;29(2):67-74. Epub 2010 Jul 15.

Liverpool Hospital, University of New South Wales, Australia.

F(18) -2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has become a well established tool in staging and assessing therapy response in lymphoma. Incidental thyroid uptake on PET is not uncommon and can pose a diagnostic and management challenge. We retrospectively evaluate the prevalence and clinical significance of incidental FDG uptake in the thyroid gland in patients with lymphoma. Read More

View Article and Full-Text PDF
  • Page 1 of 1